Immunohistochemical Analysis of Cancer Stem Cell Marker Expression in Papillary Thyroid Cancer
Cancer stem cell (CSC) markers have prognostic significance in various cancers, but their clinical significance in papillary thyroid carcinoma (PTC) has not been demonstrated. In this study, CSC markers expressed in PTC and their relationships with prognosis were evaluated. We constructed tissue mic...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2019-08-01
|
| Series: | Frontiers in Endocrinology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/article/10.3389/fendo.2019.00523/full |
| _version_ | 1818290194083741696 |
|---|---|
| author | Hye Min Kim Ja Seung Koo |
| author_facet | Hye Min Kim Ja Seung Koo |
| author_sort | Hye Min Kim |
| collection | DOAJ |
| description | Cancer stem cell (CSC) markers have prognostic significance in various cancers, but their clinical significance in papillary thyroid carcinoma (PTC) has not been demonstrated. In this study, CSC markers expressed in PTC and their relationships with prognosis were evaluated. We constructed tissue microarrays for 386 PTC cases, divided it into 42 low risk cases and 344 intermediate risk cases according to the American Thyroid Association 2009 Risk Stratification System. Immunohistochemical staining of CSC markers (CD15, CD24, CD44, CD166, and ALDH1A1) was performed, and the proportion of stained cells and immunostaining intensity were evaluated to determine positive marker expression. The relationships between CSC marker expression and other clinicopathological parameters or survival were analyzed. CD15 expression was higher in PTC with intermediate risk than in PTC with low risk (29.4 vs. 11.9%, p = 0.017). According to a multivariate analysis, CD15, CD44, CD166, and ALDH1A1 positivity were independently associated with a shorter progression-free survival (PFS) (odds ratio [OR]: 1.929, 2.960, 7.485, and 3.736; p = 0.016, p = 0.026, p < 0.001, and p = 0.006, respectively). Higher N and cancer stage were the only other clinical factors associated with a shorter PFS (OR: 2.953 and 1.898, p = 0.011 and p = 0.034). Overexpression of CSC markers in PTC was associated with shorter PFS during follow-up. Immunohistochemical staining of CSC markers may provide useful information for predicting patient outcomes. |
| first_indexed | 2024-12-13T02:24:17Z |
| format | Article |
| id | doaj.art-82913f266a32416997d53a68be7337e8 |
| institution | Directory Open Access Journal |
| issn | 1664-2392 |
| language | English |
| last_indexed | 2024-12-13T02:24:17Z |
| publishDate | 2019-08-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Endocrinology |
| spelling | doaj.art-82913f266a32416997d53a68be7337e82022-12-22T00:02:42ZengFrontiers Media S.A.Frontiers in Endocrinology1664-23922019-08-011010.3389/fendo.2019.00523445598Immunohistochemical Analysis of Cancer Stem Cell Marker Expression in Papillary Thyroid CancerHye Min KimJa Seung KooCancer stem cell (CSC) markers have prognostic significance in various cancers, but their clinical significance in papillary thyroid carcinoma (PTC) has not been demonstrated. In this study, CSC markers expressed in PTC and their relationships with prognosis were evaluated. We constructed tissue microarrays for 386 PTC cases, divided it into 42 low risk cases and 344 intermediate risk cases according to the American Thyroid Association 2009 Risk Stratification System. Immunohistochemical staining of CSC markers (CD15, CD24, CD44, CD166, and ALDH1A1) was performed, and the proportion of stained cells and immunostaining intensity were evaluated to determine positive marker expression. The relationships between CSC marker expression and other clinicopathological parameters or survival were analyzed. CD15 expression was higher in PTC with intermediate risk than in PTC with low risk (29.4 vs. 11.9%, p = 0.017). According to a multivariate analysis, CD15, CD44, CD166, and ALDH1A1 positivity were independently associated with a shorter progression-free survival (PFS) (odds ratio [OR]: 1.929, 2.960, 7.485, and 3.736; p = 0.016, p = 0.026, p < 0.001, and p = 0.006, respectively). Higher N and cancer stage were the only other clinical factors associated with a shorter PFS (OR: 2.953 and 1.898, p = 0.011 and p = 0.034). Overexpression of CSC markers in PTC was associated with shorter PFS during follow-up. Immunohistochemical staining of CSC markers may provide useful information for predicting patient outcomes.https://www.frontiersin.org/article/10.3389/fendo.2019.00523/fullcancer stem cellpapillary thyroid cancerprognosisCD15thyroid gland |
| spellingShingle | Hye Min Kim Ja Seung Koo Immunohistochemical Analysis of Cancer Stem Cell Marker Expression in Papillary Thyroid Cancer Frontiers in Endocrinology cancer stem cell papillary thyroid cancer prognosis CD15 thyroid gland |
| title | Immunohistochemical Analysis of Cancer Stem Cell Marker Expression in Papillary Thyroid Cancer |
| title_full | Immunohistochemical Analysis of Cancer Stem Cell Marker Expression in Papillary Thyroid Cancer |
| title_fullStr | Immunohistochemical Analysis of Cancer Stem Cell Marker Expression in Papillary Thyroid Cancer |
| title_full_unstemmed | Immunohistochemical Analysis of Cancer Stem Cell Marker Expression in Papillary Thyroid Cancer |
| title_short | Immunohistochemical Analysis of Cancer Stem Cell Marker Expression in Papillary Thyroid Cancer |
| title_sort | immunohistochemical analysis of cancer stem cell marker expression in papillary thyroid cancer |
| topic | cancer stem cell papillary thyroid cancer prognosis CD15 thyroid gland |
| url | https://www.frontiersin.org/article/10.3389/fendo.2019.00523/full |
| work_keys_str_mv | AT hyeminkim immunohistochemicalanalysisofcancerstemcellmarkerexpressioninpapillarythyroidcancer AT jaseungkoo immunohistochemicalanalysisofcancerstemcellmarkerexpressioninpapillarythyroidcancer |